source
- Argenx CEO Karen Massey drives $3.4 billion of acquisitions to expand beyond VyvgartArgenx, a rare‑disease biotech, announced that under its new CEO Karen Massey it has pursued two acquisitions. The deals together have a potential value of about $3.4 billion and are intended to b…
- Caldera and Evommune secure China licensing agreements for autoimmune drug assetsCaldera and Evommune announced they have entered licensing agreements with Chinese partners to bring their autoimmune drug programs to the Chinese market. The deals come as the biopharma sector is…